Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
Purity:
>95.0%
CAS Number:
[1312299-39-0]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted